Your search for ‘Smart & Biggar’ returned 2,497 results

On April 1, 2022, the Board announced it will hold a public rehearing of the matter.

Eliminate the requirement for filing clinical case reports in a filed submission or supplement, unless requested by the Minister, in order to alleviate administrative burden.

The September NEWSletter also provides information about the PMPRB’s participation in past and future events, as well as NPDUIS research initiative and activities.

On August 20, 2018, the Federal Court dismissed Valeant's PMNOC application regarding Ranbaxy's bupropion extended-release tablets and Patent No. 2,524,300.

On December 10, 2020, the Supreme Court of Canada dismissed Pfizer's application for leave to appeal (Docket No. 39150) a decision upholding an interlocutory decision...

On May 12, 2022, the Supreme Court of Canada dismissed an application by Canada RNA Biochemical.

On September 29, 2021, the Attorney General of Canada sought leave to appeal a decision of the Federal Court of Appeal (2021 FCA 157) setting aside the decision...

On September 19, 2024, the Supreme Court of Canada granted Pharmascience leave to appeal a Federal Court of Appeal decision affirming a trial decision that upheld the validity of Janssen's patent relating to paliperidone palmitate

The Advisory Panel was established by the Canadian Agency for Drugs and Technologies in Health at the request of Health Canada.

Ian McMillan, Paul Blizzard and Leanne Young's article "Dealing with Intellectual Property during Bankruptcy and Insolvency"

Patricia Folkins, Reshika Dhir, and Coralee Ridder authored the article "At the Interfaces of Al, Chemistry and Patents - Opportunities and Challenges" published by Legal Industry Reviews.

In the article, Scott MacKendrick discusses recent and potential changes to trademark law in Canada and Bill C-8 at the Academic Course on International Law and Practice.

The Internet has developed into an essential part of virtually every business, from online sales, to software as a service, to online marketing.

In September 2011, the Competition Bureau reached a settlement agreement with Beiersdorf Canada Inc., Nivea's Canadian distributor, concerning claims made in connection with its MY SILHOUETTE product. The claims were made on packaging as well as on Nivea’s website.

The Federal Court has dismissed Elanco's application for judicial review of the Minister of Health's refusal to list Canadian Patent No. 2,812,704 on the Patent Register ...

In view of the ongoing COVID-19 disruption, the Canadian Intellectual Property Office (CIPO) has further extended patent, trademark, and industrial design deadlines fixed under the relevant...

On July 25, 2025, the Office of Patented Medicines and Liaison of Health Canada released its Statistical Report 2024/2025 for the Patented Medicines (Notice of Compliance) Regulations, Data Protection...

Canada's double patenting regime presents unique challenges for patent applicants, operating without the terminal disclaimer provisions available in the United States. This creates a complex landscape where Canadian applicants face heightened vulnerability to objections, requiring careful navigation with experienced legal guidance to successfully manage patent portfolios in this strict jurisdictional environment.